Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

Lopes R. D., Al-Khatib S. M., Wallentin L., Yang H., Ansell J., Cecilia Bahit M., ...Daha Fazla

LANCET, cilt.380, sa.9855, ss.1749-1758, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 380 Sayı: 9855
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1016/s0140-6736(12)60986-6
  • Dergi Adı: LANCET
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1749-1758
  • Ankara Üniversitesi Adresli: Evet

Özet

Background The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower mortality. We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding.